Evidence map›Paper›PMID 34136411›Full record

ArticleFrontiers in oncology2021

KDF1, a Novel Tumor Suppressor in Clear Cell Renal Cell Carcinoma.

Jing-Min Zheng, Mei-Fu Gan, Hong-Yuan Yu, Lu-Xia Ye, Qing-Xin Yu, Yu-Hui Xia, Han-Xi Zhou, Jia-Qian Bao, Yi-Qing Guo

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Jing-Min ZhengDepartment of Urology, Taizhou Hospital, Wenzhou Medical University, Linhai, China.
Mei-Fu GanDepartment of Pathology, Taizhou Hospital, Wenzhou Medical University, Linhai, China.
Hong-Yuan YuDepartment of Urology, Taizhou Hospital, Wenzhou Medical University, Linhai, China.
Lu-Xia YeDepartment of Pathology, Taizhou Hospital, Wenzhou Medical University, Linhai, China.
Qing-Xin YuDepartment of Pathology, Taizhou Hospital, Wenzhou Medical University, Linhai, China.
Yu-Hui XiaDepartment of Pathology, Taizhou Hospital, Wenzhou Medical University, Linhai, China.
Han-Xi ZhouDepartment of Urology, Taizhou Hospital, Wenzhou Medical University, Linhai, China.
Jia-Qian BaoDepartment of Urology, Taizhou Hospital, Wenzhou Medical University, Linhai, China.
Yi-Qing GuoDepartment of Urology, Taizhou Hospital, Wenzhou Medical University, Linhai, China.
Wenzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

KDF1 has been identified as a key regulator of epidermal proliferation and differentiation, but it is unknown whether KDF1 is involved in the pathogenesis of malignancy. No study has reported the expression and function of KDF1 in renal cancer. To explore the pathologic significance of KDF1 in clear cell renal cell carcinoma (ccRCC), the expression level of KDF1 protein in the tumor tissue of ccRCC patients was examined by immunohistochemistry and Western blot while the expression level of KDF1 mRNA was analyzed by using the data from TCGA database. In vitro cell experiments and allogeneic tumor transplantation tests were performed to determine the effects of altered KDF1 expression on the phenotype of ccRCC cells. Both the KDF1 mRNA and protein were found to be decreasingly expressed in the tumor tissue of ccRCC patients when compared with the adjacent non-tumor control tissue. The expression level of KDF1 in the tumor tissue was found to correlate negatively with the tumor grade. Patients with higher KDF1 in the tumor tissue were found to have longer overall survival and disease-specific survival time. KDF1 was shown to be an independent factor influencing the disease-specific survival of the ccRCC patients. Overexpression of KDF1 was found to inhibit the proliferation, migration and invasion of ccRCC cells, which could be reversed by decreasing the expression of KDF1 again. ccRCC cells with KDF1 overexpression were found to produce smaller transgrafted tumors. These results support the idea that KDF1 is involved in ccRCC and may function as a tumor suppressor.

Indexed as

clear cell renal cell carcinomaKDF1prognosistumor gradetumor suppressor

Identifiers

PMID34136411
PMCPMC8201614
OpenAlexW3167659103

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.